API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-amifampridine-phosphate-tablets-60789.pdf
https://www.ema.europa.eu/en/documents/overview/amifampridine-serb-epar-medicine-overview_en.pdf
https://www.biospace.com/article/releases/kye-pharmaceuticals-announces-commercial-availability-of-firdapse-and-174-in-canada/#:~:text=(%22KYE%22)%2C%20a,Canada%2C%20is%20now%20widely%20available
https://www.globenewswire.com/news-release/2020/08/18/2079886/0/en/Catalyst-Pharmaceuticals-and-KYE-Pharmaceuticals-Announce-Agreement-to-Make-Firdapse-amifampridine-phosphate-Available-to-LEMS-Patients-in-Canada.html
http://www.globenewswire.com/news-release/2020/08/06/2074199/0/en/Catalyst-Pharmaceuticals-Firdapse-amifampridine-phosphate-Receives-Marketing-Approval-in-Canada-for-Patients-with-LEMS.html
http://www.pharmafile.com/news/532428/catalysts-lead-candidate-firdapse-falls-short-congenital-myasthenic-syndromes
https://www.reuters.com/article/us-catalyst-pharms-drugpricing/catalyst-pharma-sees-net-price-of-drug-once-free-topping-300000-idUSKCN1Q0286
https://globenewswire.com/news-release/2018/05/29/1513132/0/en/Catalyst-Pharmaceuticals-Announces-FDA-Acceptance-of-NDA-and-Priority-Review-Status-for-Firdapse-Amifampridine-Phosphate-for-Lambert-Eaton-Myasthenic-Syndrome.html